Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.

ABSTRACT:

Objective

 To compare differences in mortality between women concomitantly treated with tamoxifen and selective serotonin reuptake inhibitors (SSRIs) that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) versus tamoxifen and other SSRIs.

Design

 Population based cohort study.

Setting

 Five US databases covering individuals enrolled in private and public health insurance programs from 1995 to 2013.

Participants

 Two cohorts of women who started taking tamoxifen. In cohort 1, women started taking an SSRI during tamoxifen treatment. In cohort 2, women were already taking an SSRI when they started taking tamoxifen.

Main outcome measures

 All cause mortality in each cohort in women taking SSRIs that are potent inhibitors of CYP2D6 (paroxetine,

SUBMITTER: Donneyong MM 

PROVIDER: S-EPMC5044871 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature